SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
| Revenue (TTM) | $20.34M |
| Gross Profit (TTM) | $20.34M |
| EBITDA | $-36.54M |
| Operating Margin | -120.00% |
| Return on Equity | -53.40% |
| Return on Assets | -21.00% |
| Revenue/Share (TTM) | $3.23 |
| Book Value | $5.33 |
| Price-to-Book | 0.87 |
| Price-to-Sales (TTM) | 1.77 |
| EV/Revenue | 0.0596 |
| EV/EBITDA | 0.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1809.00% |
| Shares Outstanding | $9.93M |
| Float | $7.69M |
| % Insiders | 2.00% |
| % Institutions | 49.42% |
Volatility is currently contracting
JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator.
SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026
JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the first quarter ended March 31, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SCYX and any ticker you trade — then tracks every position and per-strategy win rate.
